Trial of investigational COMP360 psilocybin therapy

COMPASS Pathways announced that its phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression achieved a highly significant reduction in depressive symptoms with a 25mg dose, showing rapid and durable responses, although it was associated with some treatment-emergent serious adverse events.

COMP360 was generally well tolerated, with most adverse events being mild or moderate, though 12 patients experienced serious adverse events such as suicidal behavior and self-injury, which were more frequent in the 25mg group; overall, 209 out of 233 patients completed the study.

https://www.sec.gov/Archives/edgar/data/1816590/000162828021022397/exhibit991-compass6xk.htm